Alkermes (NASDAQ:ALKS) EVP David Joseph Gaffin Sells 2,034 Shares

Alkermes plc (NASDAQ:ALKS) EVP David Joseph Gaffin sold 2,034 shares of Alkermes stock in a transaction on Monday, March 2nd. The shares were sold at an average price of $29.29, for a total transaction of $59,575.86. Following the completion of the sale, the executive vice president owned 237,660 shares of the company’s stock, valued at $6,961,061.40. This represents a 0.85% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.

Alkermes Stock Down 2.3%

NASDAQ:ALKS traded down $0.68 during trading hours on Thursday, reaching $28.60. The company had a trading volume of 757,399 shares, compared to its average volume of 2,050,232. Alkermes plc has a twelve month low of $25.17 and a twelve month high of $36.32. The firm has a market cap of $4.77 billion, a price-to-earnings ratio of 19.91, a P/E/G ratio of 7.28 and a beta of 0.53. The business’s 50-day simple moving average is $31.60 and its two-hundred day simple moving average is $30.24.

Alkermes (NASDAQ:ALKS) last released its quarterly earnings data on Wednesday, February 25th. The company reported $0.29 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.43 by ($0.14). Alkermes had a return on equity of 14.91% and a net margin of 16.37%.The company had revenue of $384.55 million for the quarter, compared to the consensus estimate of $380.44 million. During the same period last year, the company earned $1.05 EPS. Alkermes’s revenue for the quarter was down 10.6% compared to the same quarter last year. Alkermes has set its FY 2026 guidance at -0.798–0.680 EPS. As a group, equities analysts predict that Alkermes plc will post 1.31 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of analysts have commented on ALKS shares. Wells Fargo & Company boosted their price target on shares of Alkermes from $37.00 to $43.00 and gave the company an “overweight” rating in a research note on Thursday, February 26th. Weiss Ratings reissued a “hold (c+)” rating on shares of Alkermes in a research report on Monday, December 29th. HC Wainwright restated a “neutral” rating and issued a $43.00 target price on shares of Alkermes in a report on Thursday, February 26th. Royal Bank Of Canada dropped their price target on shares of Alkermes from $47.00 to $45.00 and set an “outperform” rating on the stock in a research report on Thursday, February 26th. Finally, Truist Financial lifted their price target on Alkermes from $50.00 to $55.00 and gave the company a “buy” rating in a research note on Monday, November 17th. One analyst has rated the stock with a Strong Buy rating, twelve have assigned a Buy rating and five have given a Hold rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $44.07.

Institutional Trading of Alkermes

A number of large investors have recently bought and sold shares of the company. Sanctuary Advisors LLC lifted its position in shares of Alkermes by 2.7% during the 4th quarter. Sanctuary Advisors LLC now owns 12,141 shares of the company’s stock valued at $340,000 after buying an additional 315 shares during the last quarter. PNC Financial Services Group Inc. boosted its position in Alkermes by 3.5% during the fourth quarter. PNC Financial Services Group Inc. now owns 10,326 shares of the company’s stock worth $289,000 after purchasing an additional 351 shares during the period. Orion Porfolio Solutions LLC increased its stake in shares of Alkermes by 4.5% in the third quarter. Orion Porfolio Solutions LLC now owns 8,762 shares of the company’s stock worth $263,000 after purchasing an additional 376 shares in the last quarter. Horizon Investments LLC lifted its stake in shares of Alkermes by 0.9% during the 3rd quarter. Horizon Investments LLC now owns 43,002 shares of the company’s stock valued at $1,290,000 after buying an additional 387 shares in the last quarter. Finally, AMG National Trust Bank lifted its stake in shares of Alkermes by 0.6% during the 3rd quarter. AMG National Trust Bank now owns 60,175 shares of the company’s stock valued at $1,805,000 after buying an additional 388 shares in the last quarter. 95.21% of the stock is owned by hedge funds and other institutional investors.

About Alkermes

Alkermes plc is a biopharmaceutical company focused on developing innovative medicines to address unmet needs in the central nervous system (CNS). The company applies its proprietary drug delivery technologies and therapeutic expertise to advance treatments for addiction, schizophrenia, bipolar I disorder and depression. Alkermes’ portfolio includes both commercial products and a pipeline of investigational therapies designed to improve patient outcomes and support long-term disease management.

Alkermes’ commercial franchise features several approved products.